Last reviewed · How we verify
Avelumab and Pepinemab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Avelumab and Pepinemab (Avelumab and Pepinemab) — Vaccinex Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Avelumab and Pepinemab TARGET | Avelumab and Pepinemab | Vaccinex Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Avelumab and Pepinemab CI watch — RSS
- Avelumab and Pepinemab CI watch — Atom
- Avelumab and Pepinemab CI watch — JSON
- Avelumab and Pepinemab alone — RSS
Cite this brief
Drug Landscape (2026). Avelumab and Pepinemab — Competitive Intelligence Brief. https://druglandscape.com/ci/avelumab-and-pepinemab. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab